1. No category

Page 1 of 1
Quantitative Equity Report | Release: 15 Jan 2016, 23:01, GMT-06:00 | Reporting Currency: EUR | Trading Currency: EUR
Laboratorios Farmaceuticos Rovi SA ROVI
Last Close 15 Jan 2016
Quantitative Fair Value Est 15 Jan 2016
Market Cap 15 Jan 2016
Sector
Industry
14.12
15.47
697.3 Mil
d Healthcare
Biotechnology
Laboratorios Farmaceuticos Rovi SA is a pharmaceutical
company is engaged in sale of its own pharmaceutical
products and the distribution of other products.
Country of Domicile
ESP Spain
Price Versus Quantitative Fair Value
2012
2013
2014
2015
2016
2017
Sales/Share
Forecast Range
Forcasted Price
Dividend
Split
Quantitative Fair Value Estimate
30
Total Return
Quantitative Scores
24
Scores
Momentum:
—
Standard Deviation: 26.41
Liquidity: Medium
All Rel Sector Rel Country
Quantitative Moat
Narrow
Valuation
Undervalued
Quantitative Uncertainty High
Financial Health
Strong
98
31
94
79
97
27
93
76
18
95
38
87
75
12
10.20
52-Wk
16.76
4.38
5-Yr
16.76
6
ROVI
d
ESP
Undervalued
Fairly Valued
Overvalued
Source: Morningstar Equity Research
Valuation
Sector
Median
Country
Median
1.05
18.9
—
19.4
257.2
1.98
3.8
1.9
0.85
26.2
11.2
17.7
26.3
1.49
3.0
3.7
0.88
15.9
11.6
8.7
13.9
3.39
1.5
1.1
Current 5-Yr Avg
Sector
Median
Country
Median
12.5
6.7
306.4
Current 5-Yr Avg
Price/Quant Fair Value
Price/Earnings
Forward P/E
Price/Cash Flow
Price/Free Cash Flow
Dividend Yield %
Price/Book
Price/Sales
0.91
33.9
24.2
32.7
—
1.20
4.3
2.9
Profitability
Return on Equity %
Return on Assets %
Revenue/Employee (K)
13.1
8.2
219.6
18.3
9.9
216.9
Quantitative Moat
6.6
-11.1
90.9
75.4
4.8
8.5
41.8
42.5
-2.2
6.8
2.39
13.5
1.3
1.37
23.1
2.4
1.57
21.1
2.2
1.17
34.2
3.0
1.20
33.6
2.9
Total Return %
+/– Market (Morningstar World
Index)
Dividend Yield %
Price/Earnings
Price/Revenue
Morningstar RatingQ
QQQQQ
QQQQ
QQQ
QQ
Q
Financials (Fiscal Year in K)
Revenue
% Change
2010
2011
2012
2013
2014
TTM
158,645
37.8
184,706
16.4
201,923
9.3
217,587
7.8
238,047
9.4
242,398
1.8
26,003
87.1
24,582
18,985
-27.0
18,127
21,677
14.2
19,514
25,472
17.5
23,022
27,692
8.7
24,116
23,293
-15.9
20,763
Operating Income
% Change
Net Income
10.5
2.9
275.9
21,190
-5,576
15,614
9.8
12,684
-8,353
4,331
2.3
19,614
-13,720
5,894
2.9
29,816
-24,683
5,133
2.4
23,002
-25,054
-2,052
-0.9
21,598
-25,075
-3,477
-1.4
Operating Cash Flow
Capital Spending
Free Cash Flow
% Sales
Score
100
0.49
5.5
0.13
0.36
-26.5
0.11
0.39
8.3
0.12
0.46
17.9
0.00
0.48
4.3
0.12
0.42
-13.3
-0.07
0.11
1.29
50,000
0.17
2.24
50,000
0.13
2.53
49,699
0.14
2.80
49,382
0.16
3.11
—
0.17
3.29
49,382
29.2
13.0
15.5
0.84
2.0
16.6
8.2
9.8
0.84
2.0
16.2
8.7
9.7
0.90
1.8
17.0
10.1
10.6
0.95
1.6
15.9
9.7
10.1
0.96
1.6
13.1
8.2
8.6
0.96
1.6
Profitability
Return on Equity %
Return on Assets %
Net Margin %
Asset Turnover
Financial Leverage
53.2
16.4
43,089
62.7
10.3
41,246
55.2
10.7
29,135
61.0
11.7
22,578
60.3
11.6
32,032
61.4
9.6
35,905
Gross Margin %
Operating Margin %
Long-Term Debt
104,134
4.8
113,981
4.2
126,447
4.1
144,464
3.8
158,470
3.6
162,225
3.4
80
EPS
% Change
Free Cash Flow/Share
Dividends/Share
Book Value/Share
Shares Outstanding (K)
60
40
20
0
2009
2010
2011
2012
2013
2014
2015
Financial Health
Current 5-Yr Avg
Distance to Default
Solvency Score
Assets/Equity
Long-Term Debt/Equity
2016
Sector
Median
Country
Median
0.6
502.9
1.4
0.1
0.6
628.2
2.7
0.3
0.7
—
1.6
0.2
0.7
—
1.8
0.2
1-Year
3-Year
5-Year
10-Year
9.4
8.7
4.9
18.0
10.4
37.1
8.8
13.4
10.4
-2.2
11.6
38.1
15.6
14.8
0.9
13.3
19.8
25.8
-28.7
-26.8
—
—
—
—
Growth Per Share
Revenue %
Operating Income %
Earnings %
Dividends %
Book Value %
Stock Total Return %
Quarterly Revenue & EPS
Revenue (Mil)
Mar
2015
60.8
2014
57.6
2013
53.8
2012
50.9
Earnings Per Share ()
2015
0.13
2014
0.12
2013
0.11
2012
0.11
Total Equity
Fixed Asset Turns
Revenue Growth Year On Year %
Jun
60.5
58.7
55.8
53.9
Sep
56.4
57.0
51.3
48.7
Dec
—
64.8
56.7
97.0
Total
—
238.0
217.6
201.9
0.14
0.18
0.17
0.15
0.06
0.10
0.09
0.07
—
0.08
0.09
0.13
—
0.48
0.46
0.39
7.1
5.3
11.1
5.1
14.3
5.5
3.1
-1.1
-41.6
2013
2014
© Morningstar 2016. All Rights Reserved. Unless otherwise provided in a separate agreement, you may use this report only in the country in which its original distributor is based. The information, data, analyses and
opinions presented herein do not constitute investment advice; are provided solely for informational purposes and therefore is not an offer to buy or sell a security; are not warranted to be correct, complete or accurate; and
are subject to change without notice. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, the information, data,
analyses or opinions or their use. The information herein may not be reproduced, in any manner without the prior written consent of Morningstar. Please see important disclosures at the end of this report.
2015
®
ß